多靶点CAR-T细胞疗法在急性B淋巴细胞白血病中的应用

doi:10.16352/j.issn.1001-6325.2025.05.0675

基础医学与临床 ›› 2025, Vol. 45 ›› Issue (5): 675-680.doi: 10.16352/j.issn.1001-6325.2025.05.0675

多靶点CAR-T细胞疗法在急性B淋巴细胞白血病中的应用

曹金金¹, 杜娟¹, 瞿姗娜¹, 朱明宇¹, 汪洋¹, 胡翰¹, 刘滨磊^1,2*

1.湖北工业大学生命科学与健康工程学院,湖北武汉 430068;
2.武汉滨会生物科技股份有限公司,湖北武汉 436030

收稿日期:2024-12-13 修回日期:2025-03-18 出版日期:2025-05-05 发布日期:2025-04-23
通讯作者: ^* liubl@hbut.edu.cn
基金资助:
国家自然科学基金青年科学基金(82001758)

Application of multi-targeted CAR-T cell therapy in B-cell acute lymphoblastic leukemia

CAO Jinjin¹, DU Juan¹, QU Shanna¹, ZHU Mingyu¹, WANG Yang¹, HU Han¹, LIU Binlei^1,2*

1. School of Life and Health Sciences, Hubei University of Technology, Wuhan 430068;
2. Wuhan Binhui Biopharmaceutical Co. , Ltd. , Wuhan 436030, China

Received:2024-12-13 Revised:2025-03-18 Online:2025-05-05 Published:2025-04-23
Contact: ^* liubl@hbut.edu.cn

摘要/Abstract

摘要： 嵌合抗原受体T(CAR-T)细胞疗法作为一种新型细胞免疫疗法,在治疗恶性血液瘤尤其是急性B淋巴细胞白血病的临床上已经展现出较好的疗效。然而,单一靶点选择存在抗原丧失和免疫逃逸等问题,因此多靶点治疗策略逐渐受到关注。多靶点CAR-T是通过同时靶向多个肿瘤相关抗原,既能有效避免单一靶点导致的抗原逃逸问题,降低了复发风险,又有望提高治疗效果。本文主要介绍了多靶点CAR-T细胞疗法的结构类型以及治疗急性B淋巴细胞白血病的临床试验应用,期望在未来为治疗急性B淋巴细胞白血病提供参考。

关键词: 多靶点, CAR-T细胞疗法, 急性B淋巴细胞白血病, 脱靶效应, 肿瘤相关抗原

Abstract: Chimeric antigen receptor-modified T (CAR-T) cell therapy, as a new type of cellular immunotherapy, has shown good clinical efficacy in the treatment of malignant hematological tumors, especially B-cell acute lymphoblastic leukemia. However, there are problems such as antigen loss and immune evasion in single-target selection, so multi-target therapy strategies are gradually gaining attention. Multi-target CAR-T can effectively avoid antigen escape caused by a single target by targeting multiple tumor-associated antigens at the same time, reduce the risk of recurrence, and is expected to improve the therapeutic effect. This paper primarily discusses the structural types of multi-target CAR-T cell therapy and its clinical trial applications in the treatment of B-cell acute lymphoblastic leukemia (B-ALL), aiming to provide future references for the treatment of B-ALL.

Key words: multi-target, CAR-T cell therapy, B-cell acute lymphoblastic leukemia, off-target effect, tumor-associated antigen

中图分类号:

R739.6

曹金金, 杜娟, 瞿姗娜, 朱明宇, 汪洋, 胡翰, 刘滨磊. 多靶点CAR-T细胞疗法在急性B淋巴细胞白血病中的应用[J]. 基础医学与临床, 2025, 45(5): 675-680.

CAO Jinjin, DU Juan, QU Shanna, ZHU Mingyu, WANG Yang, HU Han, LIU Binlei. Application of multi-targeted CAR-T cell therapy in B-cell acute lymphoblastic leukemia[J]. Basic & Clinical Medicine, 2025, 45(5): 675-680.

参考文献

[1]Cao W,Qin K, Li F, et al.Comparative study of cancer profiles between 2020 and 2022 using global cancer statistics (GLOBOCAN)[J].Natl Cancer Cent,2024,4:128-134.
[2]Green S, Schultz L. Rational alternatives to fludarabine and cyclophosphamide-based pre-CAR lymphodepleting regimens in the pediatric and young adult B-ALLsetting[J].Curr Oncol Rep,2023,25:841-846.
[3]Maude SL,Laetsch TW,Buechner J,et al.Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia[J].N Engl J Med,2018,378:439-448.
[4]冯友琴,张棋琦,胡永仙,等.多靶点CAR-T治疗血液系统恶性肿瘤研究进展[J].临床内科杂志,2022,39:577-582.
[5]Bagley SJ,Logun M,Fraietta JA,et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results[J].Nat Med,2024,30:1320-1329.
[6]Wang W,He S,Zhang W,et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus a phase 1 open-label clinical trial[J].Ann Rheum Dis,2024,83:1304-1314.
[7]Roddie C,Lekakis LJ,Marzolini MAV,et al. Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma[J].Blood,2023,141:2470-2482.
[8]Shalabi H,Qin H,Su A,et al. CD19/22 CAR T cells in children and young adults with B-ALL phase 1 results and development of a novel bicistronic CAR[J].Blood, 2022,140:451-463.
[9]Liu Y,Deng B,Hu B,et al. Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma[J].Blood Adv,2022,6:717-730.
[10]Bachiller M,Barceló-Genestar N,Rodriguez-Garcia A,et al. ARI0003: co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma[J].Mol Ther,2025,33:317-335.
[11]Othman T,Logan AC,Muffly L,et al. The role of CAR T-cell therapy in relapsed/refractory adult B-ALL[J].Natl Compr CancNetw,2024,22:e247065. doi:10.6004/jnccn.2024.7065.
[12]Cordoba S,Onuoha S,Thomas S,et al. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia a phase 1 trial[J].Nat Med,2021,27:1797-1805.
[13]Fergusson NJ,Adeel K,Kekre N,et al.A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells[J].Front Immunol,2023,14:1178403.doi:10.3389/fimmu.2023.1178403
[14]Sining L,Qingya C,Zheng L,et al. Efficacy and safety of the second CAR-T therapy in patients with refractory/relapsed aute B-cell lymphoblastic leukemia[J].Blood,2023,142:3491. doi:10.1182/blood-2023-186718.
[15]Zah E,Lin MY,Silva-Benedict A,et al. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells[J].Cancer Immunol Res,2016,4:498-508.
[16]Martyniszyn A,Krahl AC,André MC,et al. CD20-CD19 bispecific CAR-T cells for the treatment of B-Cell malignancies[J].Hum Gene Ther,2017,28:1147-1157.
[17]Yang N,Zhang C,Zhang Y,et al. CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia[J].J Transl Med,2024,22:274. doi:10.1186/s12967-024-04990-6.
[18]Khaniya A,Rad SMAH,Halpin J,et al. Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system[J].Immunother Cancer,2024,12:e008555.doi:10.1136/jitc-2023-008555.
[19]Ren HW,Elliott N,Lye B,et al. Bispecific CAR-iNKT immunotherapy for high risk mll-rearranged acute lymphoblastic leukemia[J].Blood,2023,142: 766.doi:10.1182/blood-2023-186442.
[20]Schneider D,Xiong Y,Wu D, et al. Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models[J].Sci Transl Med,2021,13:6401.doi:10.1126/scitranslmed.abc6401.
[21]Shokouhi AR,Chen Y,Yoh HZ,et al. Engineering efficient CAR-T cells via electroactive nanoinjection[J].Adv Mater,2023,35: e2304122. doi:10.1002/adma. 202304122.
[22]Ku KS,Tang J,Chen Y,et al.Current advancements in anti-cancer chimeric antigen receptor T cell immuno-therapy and how nanotechnology may change the game[J].Int J Mol Sci,2024,25:5361. doi:10.3390/ijms25105361.
[23]Fu Y,Wang T,Ronald JA. A synthetic notch (synNotch) system linking intratumoral immune-cancer cell communication to a synthetic blood biomarker assay[J].Front Pharmacol,2023,14:1304194.doi:10.3389/fphar.2023.1304194.
[24]Bouquet L,Bôle-Richard E,Warda W,et al. Rapa Caspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cells[J].Gene Ther,2023,30:706-713.
[25]Chohan KL,Siegler EL,Kenderian SS. CAR-T cell therapy the efficacy and toxicity balance[J].Curr Hematol Malig Rep,2023,18:9-18.

多靶点CAR-T细胞疗法在急性B淋巴细胞白血病中的应用

Application of multi-targeted CAR-T cell therapy in B-cell acute lymphoblastic leukemia

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

本文评价

[1]	周昕羽, 汤继宏, 肖潇, 冯隽, 杨乐天, 徐欢, 武银银. 儿童急性B淋巴细胞白血病合并化疗诱导周围神经病变的临床特点及预后分析[J]. 基础医学与临床, 2024, 44(10): 1394-1399.
[2]	李珍, 段昭君, 罗云萍. 神经节苷脂GD2可作为肺癌干细胞一个潜在的候选标志物[J]. 基础医学与临床, 2023, 43(5): 777-784.
[3]	戴大鹏蔡剑平. 一种快速构建单靶或双靶基因位点RNAi质粒载体的方法[J]. 基础医学与临床, 2009, 29(4): 418-422.